02:15 PM EDT, 08/28/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our target to $143 from $120, 23.4x our FY 26 EPS view, a discount to A's five-year forward P/E average. We keep our FY 25 view at $5.59 and FY 26's at $6.10. Agilent ( A ) posted a solid sales performance in Q3 FY 25, with top-line revenue up 10% Y/Y, exceeding expectations despite the complex operating environment it is navigating. We think Agilent ( A ) can build on the broad-based momentum seen in Q3 as we expect the strong demand in pharma small molecule and GLP-1 to continue. We think Agilent ( A ) is benefiting from its geographic and business diversification, successfully counterbalancing funding pressures in its key U.S. market. The raised top- and bottom-line guidance is encouraging, in our view, despite an anticipated $70M tariff impact in 2H. We now see top-line sales growth of 6.4% Y/Y in 2025 vs. 3.9% Y/Y earlier, as we now expect a stronger Q4. We think Agilent's ( A ) "Ignite" program, which aims to increase productivity and focus on reinvestment, continues to be positive and could become a key differentiator.